Journal of Cardiac Failure最新文献

{"title":"Patient Sex Impacts Volume Phenotypes and Hemodynamics in Chronic Heart Failure: A Multicenter Analysis","authors":"MARAT FUDIM MD, MHS ,&nbsp;VERAPRAPAS KITTIPIBUL MD ,&nbsp;JEROEN MOLINGER MS ,&nbsp;DMITRY M. YARANOV MD ,&nbsp;WAYNE L. MILLER MD, PhD","doi":"10.1016/j.cardfail.2024.05.013","DOIUrl":"10.1016/j.cardfail.2024.05.013","url":null,"abstract":"<div><h3>Background</h3><div>Quantitative methods<span> have shown clinically significant heterogeneity in blood volume (BV) profiles in patients with chronic heart failure (HF). How patients’ sex might impact this volume heterogeneity and its relationship to cardiac hemodynamics remains to be defined.</span></div></div><div><h3>Methods</h3><div><span><span>Retrospective analysis of clinical and quantitative BV, plasma volume (PV) and red blood cell (RBC) mass data was undertaken across 3 medical centers. BV was quantitated using </span>nuclear medicine I-131-labeled </span>plasma albumin<span> indicator-dilution methodology with cardiac hemodynamics obtained within 24 hours.</span></div></div><div><h3>Results</h3><div>In an analysis of 149 males and 106 females, absolute BV was greater, on average, in males (6.9 ± 1.7 vs 5.0 ± 1.2 liters; P &lt; 0.001); however, a wide range in BVs was demonstrated in both sexes (2.9–14.5 liters). Male sex was associated with higher prevalence of large (+ 25% of normal) BV and PV expansions (36% vs 15% and 51% vs 21%, respectively; both P &lt; 0.001). In contrast, female sex was associated with higher prevalence of normal total BV (44% vs 27%; P = 0.005), PV (54% vs 27%; P &lt; 0.001), hypovolemia<span> (23% vs 11%; P = 0.005), and true anemia (42% vs 26%; P &lt; 0.001). Cardiac hemodynamics differed by sex, but only modest associations were demonstrated between volume profiles and cardiac filling pressures.</span></div></div><div><h3>Conclusions</h3><div>Findings support unique intravascular volume profiles reflecting sex-specific differences in the prevalence and distributions of total BV, PV and RBC mass profiles in patients with chronic HF. This underscores the importance of recognizing patients’ sex as a significant factor influencing volume homeostasis, which needs to be taken into account to individualize volume-management strategies effectively.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 2","pages":"Pages 379-387"},"PeriodicalIF":6.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Outcomes of Chronic Intravenous Inotropic Support in Cardiac Amyloidosis","authors":"JOHANA FAJARDO DNP ,&nbsp;MAXWELL A. HOCKSTEIN MD ,&nbsp;MANAV SINGH ,&nbsp;FRANCISCA BERMUDEZ BS ,&nbsp;TANIA VORA MD ,&nbsp;AJAY KADAKKAL MD ,&nbsp;NANA AFARI-ARMAH MD ,&nbsp;RAJA ZAGHLOL MD ,&nbsp;SAMER S. NAJJAR MD ,&nbsp;ANIRUDH RAO MD ,&nbsp;FAROOQ H. SHEIKH MD","doi":"10.1016/j.cardfail.2024.07.021","DOIUrl":"10.1016/j.cardfail.2024.07.021","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 2","pages":"Pages 471-476"},"PeriodicalIF":6.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142000011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Right Ventriculoarterial Coupling Surrogates and Long-Term Survival in LVAD Recipients: Results of the ASSIST-ICD Multicentric Registry","authors":"MAXIME BENEYTO MD MS ,&nbsp;RAPHAËL MARTINS MD, PhD ,&nbsp;VINCENT GALAND MD ,&nbsp;MICHEL KINDO MD, PhD ,&nbsp;CLÉMENT SCHNEIDER MD ,&nbsp;ALEXANDRE SEBESTYEN MD ,&nbsp;AUDE BOIGNARD MD ,&nbsp;LAURENT SEBBAG MD ,&nbsp;MATTEO POZZI MD, PhD ,&nbsp;THIBAUD GENET MD ,&nbsp;THIERRY BOURGUIGNON MD ,&nbsp;ANNE-CÉLINE MARTIN MD, PhD ,&nbsp;PAUL ACHOUH MD, PhD ,&nbsp;FABRICE VANHUYSE MD, PhD ,&nbsp;HUGUES BLANG MD ,&nbsp;CHARLES HENRI DAVID MD, PhD ,&nbsp;MAGALI MICHEL MD ,&nbsp;FRÉDÉRIC ANSELME MD, PhD ,&nbsp;PIERRE-YVES LITZLER MD, PhD ,&nbsp;MARIE JUNGLING MD ,&nbsp;CLEMENT DELMAS MD, PhD","doi":"10.1016/j.cardfail.2024.05.007","DOIUrl":"10.1016/j.cardfail.2024.05.007","url":null,"abstract":"<div><h3>Background</h3><div>Prediction of outcomes remains an unmet need in candidates for LVADs. The development of right-heart failure portends an excess in mortality rates, but imaging parameters of right ventricular systolic function have failed to demonstrate a prognostic role. By integrating pulmonary pressure, right ventriculoarterial coupling could fill this gap.</div></div><div><h3>Methods</h3><div>The ASSIST-ICD registry was used to test right ventriculoarterial coupling as a surrogate parameter at implantation for the prediction of all-cause mortality.</div></div><div><h3>Results</h3><div>The ratio of the tricuspid annular-plane systolic excursion over the estimated systolic pulmonary pressure (TAPSE/sPAP) was not associated with long-term survival in univariate analysis (<em>P</em> = 0.89), nor was the pulmonary artery pulsatility index (PAPi) (<em>P</em> = 0.13). Conversely, the ratio of the right atrial pressure over the pulmonary capillary wedge pressure (RAP/PCWP) was associated with all-cause mortality (<em>P</em> &lt; 0.01). After taking tricuspid regurgitation severity, LVAD indication, LVAD model, age, blood urea nitrogen levels, and pulmonary vascular resistance into account, RAP/PCWP remained associated with survival (HR 1.35 [1.10 – 1.65]; <em>P</em> &lt; 0.01).</div></div><div><h3>Conclusion</h3><div>Among pre-implant RVAC surrogates, only RAP/PCWP was associated with long-term all-cause mortality in LVAD recipients. This association was independent of established risk factors.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 2","pages":"Pages 388-396"},"PeriodicalIF":6.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141293447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Feasibility of an Implanted Inferior Vena Cava Sensor for Accurate Volume Assessment: FUTURE-HF2 Trial","authors":"NIR URIEL ,&nbsp;KUNJAN BHATT ,&nbsp;RAMI KAHWASH ,&nbsp;THOMAS R. MCMINN ,&nbsp;MANESH R. PATEL ,&nbsp;SCOTT LILLY ,&nbsp;JOHN R. BRITTON ,&nbsp;LOUISE CORCORAN ,&nbsp;BARRY R. GREENE ,&nbsp;ROBYN M. KEALY ,&nbsp;ANNETTE KENT ,&nbsp;WILLIAM S. SHERIDAN ,&nbsp;AJAY J. KIRTANE ,&nbsp;SANJUM S. SETHI ,&nbsp;JEREMIAH P. DEPTA ,&nbsp;SCOTT C. FEITELL ,&nbsp;GABRIEL SAYER ,&nbsp;MARAT FUDIM","doi":"10.1016/j.cardfail.2024.09.003","DOIUrl":"10.1016/j.cardfail.2024.09.003","url":null,"abstract":"<div><h3>Background</h3><div>A novel implantable sensor has been designed to measure the inferior vena cava (IVC) area accurately so as to allow daily monitoring of the IVC area and collapse to predict congestion in heart failure (HF).</div></div><div><h3>Methods</h3><div>A prospective, multicenter, single-arm, Early Feasibility Study enrolled 15 patients with HF (irrespective of ejection fraction) and with an HF event in the previous 12 months, an elevated NT-proBNP level, and receiving ≥ 40 mg of furosemide equivalent. Primary endpoints included successful deployment without procedure-related (30 days) or sensor-related complications (3 months) and successful data transmission to a secure database (3 months). Accuracy of sensor-derived IVC area, patient adherence, NYHA classification, and KCCQ were assessed from baseline to 3 months. Patient-specific signal alterations were correlated with clinical presentation to guide interventions.</div></div><div><h3>Results</h3><div>Fifteen patients underwent implantation: 66 ± 12 years; 47% female; 27% with HFpEF, NT-ProBNP levels 2569 (median, IQR: 1674–5187, ng/L; 87% NYHA class III). All patients met the primary safety and effectiveness endpoints. Sensor-derived IVC areas showed excellent agreement with concurrent computed tomography (R² = 0.99, mean absolute error = 11.15 mm²). Median adherence to daily readings was 98% (IQR: 86%–100%) per patient-month. A significant improvement was seen in NYHA class and a nonsignificant improvement was observed in KCCQ.</div></div><div><h3>Conclusions</h3><div>Implantation of a novel IVC sensor (FIRE1) was feasible, uncomplicated and safe. Sensor outputs aligned with clinical presentations and improvements in clinical outcomes. Future investigation to establish the IVC sensor remote management of HF is strongly warranted.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 2","pages":"Pages 369-376"},"PeriodicalIF":6.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142347365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clonal Hematopoiesis of Indeterminate Potential and Long-term Outcomes in Heart Transplantation","authors":"PANAGIOTIS SIMITSIS MD, MSc ,&nbsp;ANJU NOHRIA MD ,&nbsp;JANE KELLEHER MSc ,&nbsp;JACINTHE BOULET MDCM, MPH ,&nbsp;MAURO R.B. WANDERLEY Jr MD, PhD ,&nbsp;PRADEEP NATARAJAN MD, MMSc ,&nbsp;PETER LIBBY MD ,&nbsp;MANDEEP R. MEHRA MD, MSc","doi":"10.1016/j.cardfail.2024.05.011","DOIUrl":"10.1016/j.cardfail.2024.05.011","url":null,"abstract":"<div><h3>Background</h3><div><span>Clonal hematopoiesis of indeterminate potential (CHIP) mutations, a trait of aging, has been associated with the progression of cardiovascular disease and the development of </span>malignancy. Uncertainty prevails regarding a robust association between CHIP and heart-transplantation (HT) outcomes.</div></div><div><h3>Objectives</h3><div><span>To determine the prevalence of CHIP mutations in HT and their association with long-term outcomes, including cardiac allograft vasculopathy (CAV), </span>graft failure, malignancy, and all-cause mortality.</div></div><div><h3>Methods</h3><div><span>We conducted a mixed retrospective-prospective observational study of HT recipients with targeted sequencing for CHIP mutations (variant allele frequency [VAF] of ≥ 2%). The primary composite outcome was the first occurrence of CAV grade ≥ 2, graft failure, malignancy, cardiac </span>retransplantation, or all-cause death. Secondary outcomes were the individual components of the composite primary outcome. Sensitivity analyses with base-case and extreme scenarios were performed.</div></div><div><h3>Results</h3><div>Among 95 HT recipients, 30 had CHIP mutations (31.6%). <span><span>DNMT3A</span></span> mutations were most common (44.7%), followed by <em>PPM1D</em> (13.2%), <span><em>SF3B1</em></span> (10.5%), <em>TET2</em> (7.9%), and <em>TP53</em> (7.9%). The only significant independent predictor of CHIP was age at enrollment or age at transplantation. After multivariable adjustment, CHIP mutations were not associated with the primary outcome, which occurred in 44 (46.3%) patients (HR = 0.487; 95% CI:0.197–1.204; <em>P</em> = 0.119), nor were they associated with mlalignancy alone, or death.</div></div><div><h3>Conclusion</h3><div>We demonstrated no association between CHIP mutations and post-transplant outcomes, including CAV, graft failure, malignancy, and all-cause mortality. In line with previously published data, our analysis provides additional evidence about the lack of clinical value of using CHIP mutations as a biomarker for surveillance in outcomes after HT.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 2","pages":"Pages 400-410"},"PeriodicalIF":6.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141405124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardio-Oncology and Heart Failure: AL Amyloidosis for the Heart Failure Clinician: a Supplement to the Scientific Statement from the Heart Failure Society of America","authors":"MICHELLE WEISFELNER BLOOM MD, Co-Chair ,&nbsp;JACQUELINE B. VO PhD, RN, MPH ,&nbsp;JO E. RODGERS PharmD, BCPS, BCCP ,&nbsp;ALANA M. FERRARI PharmD, BCOP ,&nbsp;ANJU NOHRIA MD, MSc ,&nbsp;ANITA DESWAL MD, MPH ,&nbsp;RICHARD K. CHENG MD, MSc ,&nbsp;MICHELLE M. KITTLESON MD, PhD ,&nbsp;JENICA N. UPSHAW MD, MS ,&nbsp;NICOLAS PALASKAS MD ,&nbsp;ANNE BLAES MD MS ,&nbsp;SHERRY-ANN BROWN MD, PhD ,&nbsp;BONNIE KY MD, MSCE ,&nbsp;DANIEL LENIHAN MD ,&nbsp;MATHEW S. MAURER MD ,&nbsp;ANECITA FADOL PhD, NP ,&nbsp;KERRY SKURKA RN, BSN ,&nbsp;CHRISTINE CAMBARERI PharmD, BCOP ,&nbsp;ANA BARAC MD, PhD, (Co-Chair)","doi":"10.1016/j.cardfail.2024.08.046","DOIUrl":"10.1016/j.cardfail.2024.08.046","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 2","pages":"Pages 456-463"},"PeriodicalIF":6.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142466331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sense the Wave Coming?","authors":"KATHLEEN L. MORRIS DO, FACC,&nbsp;ASHWIN RAVICHANDRAN MD, MPH, FACC","doi":"10.1016/j.cardfail.2025.01.001","DOIUrl":"10.1016/j.cardfail.2025.01.001","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 2","pages":"Pages 377-378"},"PeriodicalIF":6.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Similar Goals, Divergent Paths: Exploring Approaches Towards Hepatitis C Treatment Protocols in Heart Transplantation.","authors":"Roopa A Rao, Sonu Abraham, Amanda R Vest, Mrudula Munnagala, Anju Bhardwaj, Johanas Contreras, Indranee Rajapreyer, Shelley Hall","doi":"10.1016/j.cardfail.2024.11.020","DOIUrl":"https://doi.org/10.1016/j.cardfail.2024.11.020","url":null,"abstract":"<p><strong>Background: </strong>Heart transplantation from hepatitis C positive donors is on the rise, yet there exists divergence in approaches to managing recipients of these organs. Practices range from prophylactic treatment of recipients prior to transplantation to delayed treatment following the detection of viremia, with no established consensus on the optimal approach.</p><p><strong>Methods: </strong>An online survey was conducted among the heart transplant centers in the United States of America and Canada from January 2023 to February 2024. The survey gathered comprehensive information from the institutions regarding direct antiviral (DAA) therapies used, timing and duration of DAA, frequency of viral load testing, adverse effects, virological response and immunosuppressive therapy modifications. The treatment pathways were categorized based on the timing of treatment initiation into prophylactic, preemptive, or reactive approaches. Analysis was restricted to US adult transplant programs that had an HCV transplant protocol and performed at least one HCV NAT positive transplant. The SRTR database was queried for total heart transplants using HCV NAT positive donors.</p><p><strong>Results: </strong>Of 122 heart transplant programs, 35 (28.7%) institutions responded. 689 heart transplants (49.1%) using HCV NAT positive donors were captured across institutions. Among 30 US institutions performing adult heart transplantation with HCV NAT positive donor hearts, 5 (16.7%) used prophylactic, 9 (30%) preemptive, and 16 (53.3%) reactive treatment pathways. Most employed pan-genotype DAA therapies for a median of 12 weeks. Significant heterogeneity existed in treatment and monitoring protocols.</p><p><strong>Conclusion: </strong>Practice patterns for management of HCV NAT positive donor hearts vary significantly. Establishing registries and Randomized Control Trials for these patients is crucial for guiding future practices.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heart Failure in Patients with Cancer – A Patient's Perspective","authors":"Cynthia Chauhan MSW","doi":"10.1016/j.cardfail.2024.08.047","DOIUrl":"10.1016/j.cardfail.2024.08.047","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 2","pages":"Page 464"},"PeriodicalIF":6.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142466332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rebranding at the Intersections: A New Look For Our Field","authors":"Anuradha Lala MD ,&nbsp;Robert J. Mentz MD","doi":"10.1016/j.cardfail.2025.01.007","DOIUrl":"10.1016/j.cardfail.2025.01.007","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 2","pages":"Page 353"},"PeriodicalIF":6.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143379185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}